Datapoint: FDA Approves Host of Vyvanse Generics

As the nationwide Adderall shortage continues, the FDA last week approved the first generic versions of Takeda’s blockbuster ADHD drug Vyvanse (lisdexamfetamine dimesylate). Manufacturers of the newly approved generics include Actavis, Mylan, Sun Pharmaceutical and Teva. For the treatment of ADHD, Vyvanse holds covered or better status for 88% of all insured lives under the pharmacy benefit. About 43% of lives have preferred access to Vyvanse without utilization management restrictions.

SOURCE: MMIT Analytics, as of 8/31/23

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today